lansoprazole IV
Selected indexed studies
- Vonoprazan as a Long-term Maintenance Treatment for Erosive Esophagitis: VISION, a 5-Year, Randomized, Open-label Study. (Clin Gastroenterol Hepatol, 2025) [PMID:39209187]
- New Drugs IV. (, 1994) [PMID:38620469]
- [Pharmacological and clinical profile of lansoprazole (Takepron IV injection 30 mg)]. (Nihon Yakurigaku Zasshi, 2008) [PMID:18277015]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Clinical pharmacokinetics of nebivolol: a systematic review. (2023) pubmed
- Vonoprazan as a Long-term Maintenance Treatment for Erosive Esophagitis: VISION, a 5-Year, Randomized, Open-label Study. (2025) pubmed
- New Drugs IV. (1994) pubmed
- [Pharmacological and clinical profile of lansoprazole (Takepron IV injection 30 mg)]. (2008) pubmed
- Comparison of Tegoprazan and Lansoprazole in Patients With Erosive Esophagitis up to 4 Weeks: A Multi-Center, Randomized, Double-Blind, Active-Comparator Phase 4 Trial. (2025) pubmed
- Neuroprotective effect of lansoprazole against cisplatin-induced brain toxicity: Role of Nrf2/ARE and Akt/P53 signaling pathways. (2023) pubmed
- Inhibition mechanism of potential antituberculosis compound lansoprazole sulfide. (2024) pubmed
- Intravenous proton pump inhibitors. (2006) pubmed
- Lansoprazole and omeprazole in the prevention of relapse of reflux oesophagitis: a long-term comparative study. (1998) pubmed
- Comparison of the enteral and intravenous lansoprazole pharmacodynamic responses in critically ill patients. (2008) pubmed